OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium

OKYO Pharma (Nasdaq: OKYO), a clinical-stage biopharma focused on neuropathic corneal pain and anterior segment eye diseases, will participate in a fireside chat at the Piper Sandler 2026 Virtual Ophthalmology Symposium.

Rhea-AI Summary

OKYO Pharma (Nasdaq: OKYO), a clinical-stage biopharma focused on neuropathic corneal pain and anterior segment eye diseases, will participate in a fireside chat at the Piper Sandler 2026 Virtual Ophthalmology Symposium.

The virtual event is scheduled for Thursday, July 9, 2026 at 8:30 AM ET, featuring CEO Robert J. Dempsey and CMO Flavio Mantelli, moderated by Biren Amin of Piper Sandler.

Argus Jul 7 session 5 alerts

+8.70% close to close 1.6x rel. volume Open Argus

Details

Market move: OKYO +8.70% in the Jul 7 session. Piper Sandler ophthalmology fireside chat

+4.2% Peak in 2 hr 22 min

$82.39M Market Cap

On Jul 7, the day this news came out, OKYO closed 8.70% above the previous close. Argus tracked a peak move of +4.2% during that session. Our momentum scanner recorded 5 alerts for this stock that day. Relative volume reached 1.6x the daily average during tracking.

Data tracked by StockTitan Argus for the Jul 7 session.

Market Context

On Jul 7, the day this news came out, the stock closed 8.7% above the previous close. A strong gain ...

Analysis

On Jul 7, the day this news came out, the stock closed 8.7% above the previous close. A strong gain following this fireside chat appearance would echo prior conference-linked interest, though past reactions were mixed, such as a -3.8% move after May conference news. Any sustained strength could be tempered by dilution capacity under the active shelf.

Key Figures

Symposium date: July 9, 2026 Fireside chat time: 8:30 AM ET

Symposium date

July 9, 2026

Piper Sandler Virtual Ophthalmology Symposium

Fireside chat time

8:30 AM ET

OKYO presentation slot at Piper Sandler symposium

Historical Context

5 past events · Latest: May 19

5 events

1. May 19

   Advisory board appointment

   24h Move

   -0.0%

   Appointment of international ophthalmology expert to Scientific Advisory Board.

2. Apr 29

   Conference participation

   24h Move

   -3.8%

   CEO and CSO presentations at May scientific conferences on urcosimod data.

3. Apr 07

   Data presentation

   24h Move

   +1.9%

   Planned Phase 2 urcosimod data presentation and SAB meeting at ASCRS.

4. Mar 19

   Insider share purchase

   24h Move

   +0.0%

   Director Brancaccio purchased additional ordinary shares on NASDAQ.

5. Mar 19

   Insider share purchase

   24h Move

   +0.0%

   Executive chairman-related entity acquired additional ordinary shares.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

neuropathic corneal pain, anterior segment

2 terms

neuropathic corneal pain medical

"developing investigational therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic, often severe eye pain caused by damage or malfunction in the tiny nerves of the cornea, where the eye surface can feel burning, stinging, or like something is in it despite little visible damage. It matters to investors because it represents a persistent, hard-to-treat medical need that drives demand for new drugs, diagnostics, devices and regulatory approvals, similar to how fixing a frayed electrical wire stops false alarm signals.

anterior segment medical

"and anterior segment eye diseases, today announced participation"

The anterior segment is the front portion of the eye that includes the cornea, iris, pupil, lens and the fluid-filled front chambers. Think of it as the eye's entrance hall where light first passes and pressure is regulated; its health matters to investors because many drugs, medical devices and surgical procedures target these structures, affecting clinical trial needs, regulatory approval and market demand.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced participation at the Piper Sandler Virtual Ophthalmology Symposium being held on Thursday, July 9, 2026.

Details of the event are as follows:

Presenters: Robert J. Dempsey, Chief Executive Officer, Flavio Mantelli MD, PhD, Chief Medical Officer

Date/Time: Thursday, July 9 at 8:30 AM ET

Moderator: Biren Amin, Managing Director, Healthcare Equity Research, Piper Sandler & Co.

Location: Virtual

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in patients with NCP and plans to initiate a 150-patient Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will OKYO Pharma (NASDAQ: OKYO) present at the Piper Sandler 2026 Virtual Ophthalmology Symposium?

OKYO Pharma will present at the Piper Sandler 2026 Virtual Ophthalmology Symposium on Thursday, July 9, 2026 at 8:30 AM ET. According to OKYO Pharma, the company’s leadership will join a virtual fireside chat focused on ophthalmology topics.

Who will represent OKYO Pharma (OKYO) at the Piper Sandler 2026 Virtual Ophthalmology Symposium fireside chat?

OKYO Pharma will be represented by CEO Robert J. Dempsey and CMO Flavio Mantelli at the fireside chat. According to OKYO Pharma, both executives will discuss the company’s investigational therapies targeting neuropathic corneal pain and anterior segment eye diseases.

What is the focus of OKYO Pharma’s business ahead of the July 9, 2026 Piper Sandler symposium appearance?

OKYO Pharma focuses on developing investigational therapies for neuropathic corneal pain and anterior segment eye diseases. According to OKYO Pharma, its clinical-stage pipeline underpins the company’s participation in the Piper Sandler 2026 Virtual Ophthalmology Symposium fireside chat.

How can investors attend OKYO Pharma’s fireside chat at the Piper Sandler 2026 Virtual Ophthalmology Symposium?

Investors can attend OKYO Pharma’s session virtually, as the Piper Sandler 2026 Ophthalmology Symposium is an online event. According to OKYO Pharma, the fireside chat will be held remotely on Thursday, July 9, 2026 at 8:30 AM ET.

Who is moderating OKYO Pharma’s July 9, 2026 fireside chat at the Piper Sandler Virtual Ophthalmology Symposium?

The fireside chat will be moderated by Biren Amin, Managing Director, Healthcare Equity Research at Piper Sandler. According to OKYO Pharma, Amin will lead the discussion with CEO Robert J. Dempsey and CMO Flavio Mantelli during the virtual event.